映恩生物-B(9606.HK):核心产品快速推进 FIC管线迈向全球

中信建投证券
08 May

核心观点映恩生物是国内专注于ADC 领域龙头Biotech。依托四大自主开发的核心ADC 技术平台,构建了具有高度差异化的新一代产品管线。目前拥有12 款自主研发的ADC 候选药物,其中7 款已进入临床阶段,广泛布局于多个高潜力适应症。公司进度最快的DB-1303 差异化布局HER2+EC,有望于25 年递交海外上市申请。全球进度领先的DB-1311 去年底ESMO Asia 公布出色早期数据,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10